Rel-Lifirafenib
Rel-Lifirafenib (rel-BGB-283) is the relative configuration of Lifirafenib. Lifirafenib is a potent Raf Kinase and EGFR inhibitor[1].
Product Specifications
CAS Number
1446090-77-2
Product Name Alternative
Rel-BGB-283
UNSPSC
12352005
Hazard Statement
H302-H315-H319-H335
Target
EGFR; Raf
Type
Reference compound
Related Pathways
JAK/STAT Signaling; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/rel-lifirafenib.html
Solubility
10 mM in DMSO
Smiles
O=C1NC2=NC=CC(OC3=CC=C(O[C@]4([H])[C@@]5([H])[C@H]4C6=NC7=CC=C(C(F)(F)F)C=C7N6)C5=C3)=C2CC1.[Relativestereochemistry]
Molecular Formula
C25H17F3N4O3
Molecular Weight
478.42
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501
References & Citations
[1]Tang Z, et al. BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers. Mol Cancer Ther. 2015 Oct;14 (10) :2187-97.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
LC431978 20 µg
WDR23 (DCAF11) (NM_001163484) Human Over-expression Lysate
Sign In for Pricing
View Details 
BNC471953-100 1x 100 µL
CD21 (Mature B-Cell & Follicular Dendritic Cell Marker) (CR2/1953), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details